The Value of ADAMTS13 in Predicting Clinical Outcomes in Patients With Acute Ischemic Stroke Receiving Thrombolysis

Objective: To determine the association between baseline ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) antigen level and 90-days clinical outcome in patients with acute ischemic stroke (AIS) receiving recombinant tissue plasminogen activator (rt-PA) thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Ya, Chen, Xin, Ye, Xiaofei, Sun, Haiyan, Wu, Fei, Dong, Qiang, Cheng, Xin, Wu, Danhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412597/
https://www.ncbi.nlm.nih.gov/pubmed/32849241
http://dx.doi.org/10.3389/fneur.2020.00799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412597/
https://www.ncbi.nlm.nih.gov/pubmed/32849241
http://dx.doi.org/10.3389/fneur.2020.00799

Ejemplares similares